Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

Aldo M Roccaro1, Irene M Ghobrial1, Simona Blotta1, Steven P Treon1, Michele Malagola2, Kenneth C Anderson1, Paul G Richardson1, Domenico Russo21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Unit of Blood Diseases and Cell Therapies, Unive...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aldo M Roccaro, Irene M Ghobrial, Simona Blotta, Steven P Treon, Michele Malagola, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bad66ef67c3943c793fa1f520c88a596
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bad66ef67c3943c793fa1f520c88a596
record_format	dspace
spelling	oai:doaj.org-article:bad66ef67c3943c793fa1f520c88a5962021-12-02T05:54:08ZAdvances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias1177-54751177-5491https://doaj.org/article/bad66ef67c3943c793fa1f520c88a5962008-09-01T00:00:00Zhttp://www.dovepress.com/advances-in-the-treatment-of-monoclonal-gammopaties-the-emerging-role--a2292https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Aldo M Roccaro1, Irene M Ghobrial1, Simona Blotta1, Steven P Treon1, Michele Malagola2, Kenneth C Anderson1, Paul G Richardson1, Domenico Russo21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Unit of Blood Diseases and Cell Therapies, University of Brescia Medical School, Brescia, ItalyAbstract: The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of the MM cells with the bone marrow microenvironment and the signaling pathways that are dysregulated in this process, a number of novel therapeutic agents are now available. Specifically, three novel agents with a specific-targeted anti-MM activity, have been FDA-approved for the treatment of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing a key role in the treatment of MM. The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenstr&ouml;m&rsquo;s macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials.Keywords: monoclonal gammopaties, targeted therapies Aldo M RoccaroIrene M GhobrialSimona BlottaSteven P TreonMichele Malagolaet alDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 419-431 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Aldo M Roccaro Irene M Ghobrial Simona Blotta Steven P Treon Michele Malagola et al Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
description	Aldo M Roccaro1, Irene M Ghobrial1, Simona Blotta1, Steven P Treon1, Michele Malagola2, Kenneth C Anderson1, Paul G Richardson1, Domenico Russo21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Unit of Blood Diseases and Cell Therapies, University of Brescia Medical School, Brescia, ItalyAbstract: The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of the MM cells with the bone marrow microenvironment and the signaling pathways that are dysregulated in this process, a number of novel therapeutic agents are now available. Specifically, three novel agents with a specific-targeted anti-MM activity, have been FDA-approved for the treatment of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing a key role in the treatment of MM. The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenstr&ouml;m&rsquo;s macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials.Keywords: monoclonal gammopaties, targeted therapies
format	article
author	Aldo M Roccaro Irene M Ghobrial Simona Blotta Steven P Treon Michele Malagola et al
author_facet	Aldo M Roccaro Irene M Ghobrial Simona Blotta Steven P Treon Michele Malagola et al
author_sort	Aldo M Roccaro
title	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
title_short	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
title_full	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
title_fullStr	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
title_full_unstemmed	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
title_sort	advances in the treatment of monoclonal gammopaties: the emerging role of targeted therapy in plasma cell dyscrasias
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/bad66ef67c3943c793fa1f520c88a596
work_keys_str_mv	AT aldomroccaro advancesinthetreatmentofmonoclonalgammopatiestheemergingroleoftargetedtherapyinplasmacelldyscrasias AT irenemghobrial advancesinthetreatmentofmonoclonalgammopatiestheemergingroleoftargetedtherapyinplasmacelldyscrasias AT simonablotta advancesinthetreatmentofmonoclonalgammopatiestheemergingroleoftargetedtherapyinplasmacelldyscrasias AT stevenptreon advancesinthetreatmentofmonoclonalgammopatiestheemergingroleoftargetedtherapyinplasmacelldyscrasias AT michelemalagola advancesinthetreatmentofmonoclonalgammopatiestheemergingroleoftargetedtherapyinplasmacelldyscrasias AT etal advancesinthetreatmentofmonoclonalgammopatiestheemergingroleoftargetedtherapyinplasmacelldyscrasias
_version_	1718400192382763008

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

Ejemplares similares